All posts by Doug Hinerfeld


Moving Toward the Clinic- Leveraging Xenograft Models for Preclinical Anti-Cancer Studies

The use of cancer cell lines for in vitro studies of anti-cancer agents remains a primary component of preclinical drug development. These studies, however, struggle with significant pitfalls given the unique biology of cancer cell lines and the artificial assay...

/ November 2, 2017